Zentalis Pharmaceuticals Announces First Patient Dosed In The Phase 1/2 Study Of Zn-C3 In Combination With Gemcitabine In Patients With Osteosarcoma

Zentalis Pharmaceuticals Inc. published this content on September 13, 2021, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 06, 2026 at 18:27 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]